Literature DB >> 20573388

Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma.

Hwang Gyun Jeon1, In Gab Jeong, Jungbum Bae, Jeong Woo Lee, Jae-Kyung Won, Jin Ho Paik, Hyeon Hoe Kim, Sang Eun Lee, Eunsik Lee.   

Abstract

OBJECTIVES: To investigate the prognostic value of Ki-67, cyclooxygenase-2 (COX-2), E-cadherin, and retinoblastoma protein (pRB) in patients with urothelial carcinoma of the upper urinary tract.
METHODS: From January 1998 to December 2005, the specimens from 107 patients with urothelial carcinoma of the upper urinary tract who had undergone nephroureterectomy were analyzed. The expression of Ki-67, COX-2, E-cadherin, and pRB was examined by immunochemistry on tissue microarray sections. The correlation of the immunoreactivity with the pathologic parameters and progression-free and cancer-specific survival were examined.
RESULTS: Ki-67 and COX-2 were overexpressed in 26 (24%) and 38 patients (36%), respectively. The loss of E-cadherin expression was observed in 66 patients (62%). Altered pRB expression was found in 37 patients (34%). Overexpression of Ki-67 (P = .041 and P = .006, respectively) and COX-2 (P = .002 and P = .001, respectively) was associated with the pathologic stage and grade. Multivariate analysis showed that Ki-67 overexpression (P = .002), T stage (P = .009), and lymph node metastases (P = .009) were independent predictors of progression-free survival. In addition, Ki-67 overexpression (P = .007) and pathologic T stage (P = .003) were independent predictors of cancer-specific survival. No association was found between the pathologic findings and prognosis and the other markers (E-cadherin and pRB).
CONCLUSIONS: Our results suggest that Ki-67 overexpression is an independent predictor of the progression of urothelial carcinoma of the upper urinary tract. Patients with Ki-67 overexpression should be followed up more closely. In addition, they might be candidates for future prospective therapy trials. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20573388     DOI: 10.1016/j.urology.2010.03.070

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  12 in total

Review 1.  Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.

Authors:  Aurélie Mbeutcha; Morgan Rouprêt; Ashish M Kamat; Pierre I Karakiewicz; Nathan Lawrentschuk; Giacomo Novara; Jay D Raman; Christian Seitz; Evanguelos Xylinas; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-21       Impact factor: 4.226

Review 2.  Distinct patterns and behaviour of urothelial carcinoma with respect to anatomical location: how molecular biomarkers can augment clinico-pathological predictors in upper urinary tract tumours.

Authors:  David R Yates; James W F Catto
Journal:  World J Urol       Date:  2012-09-18       Impact factor: 4.226

3.  Clinicopathological and prognostic significance of EZH2 expression in upper urinary tract carcinoma.

Authors:  Akimasa Hayashi; Teppei Morikawa; Taketo Kawai; Haruki Kume; Shumpei Ishikawa; Yukio Homma; Masashi Fukayama
Journal:  Virchows Arch       Date:  2014-01-21       Impact factor: 4.064

4.  Increased nucleophosmin expression is a strong predictor of recurrence and prognosis in patients with N0M0 upper tract urothelial carcinoma undergoing radical nephroureterectomy.

Authors:  Harutake Sawazaki; Keiichi Ito; Takako Asano; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Kenji Seguchi; Tomohiko Asano
Journal:  World J Urol       Date:  2016-11-24       Impact factor: 4.226

5.  Expression of survivin in squamous cell carcinoma and transitional cell carcinoma of the urinary bladder: a comparative immunohistochemical study.

Authors:  Rania Makboul; Abeer E L-Refaiy M Refaiy; Fatma Ahmed Mahmoud Badary; Islam F Abdelkawi; Axel S Merseburger; Rabab Ahmed Ahmed Mohammed
Journal:  Korean J Urol       Date:  2015-01-08

6.  Expression and Significance of COX-2 and Ki-67 in Hepatolithiasis with Bile Duct Carcinoma.

Authors:  Ping Wang; Yu He; Xiaodong Ma; Beiwang Sun; Binyuan Huang; Canhua Zhu; Yanmin Liu
Journal:  Med Sci Monit       Date:  2015-10-01

Review 7.  Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature.

Authors:  Aurélie Mbeutcha; Romain Mathieu; Morgan Rouprêt; Kilian M Gust; Alberto Briganti; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Transl Androl Urol       Date:  2016-10

8.  Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression.

Authors:  Eiji Kashiwagi; Satoshi Inoue; Taichi Mizushima; Jinbo Chen; Hiroki Ide; Takashi Kawahara; Leonardo O Reis; Alexander S Baras; George J Netto; Hiroshi Miyamoto
Journal:  Br J Cancer       Date:  2017-11-09       Impact factor: 7.640

9.  Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study.

Authors:  Ricardo L Favaretto; Atessa Bahadori; Romain Mathieu; Andrea Haitel; Bernhard Grubmüller; Vitaly Margulis; Jose A Karam; Morgan Rouprêt; Christian Seitz; Pierre I Karakiewicz; Isabela W Cunha; Stenio C Zequi; Christopher G Wood; Alon Z Weizer; Jay D Raman; Mesut Remzi; Nathalie Rioux-Leclercq; Solene Jacquet-Kammerer; Karim Bensalah; Yair Lotan; Alexander Bachmann; Michael Rink; Alberto Briganti; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-04-29       Impact factor: 4.226

10.  Reduce bladder cancer recurrence in patients treated for upper urinary tract urothelial carcinoma: The REBACARE-trial.

Authors:  T van Doeveren; P J van Leeuwen; K K H Aben; M van der Aa; M Barendrecht; E R Boevé; E B Cornel; A G van der Heijden; K Hendricksen; W Hirdes; A Kooistra; B Kroon; A M Leliveld; R P Meijer; H van Melick; B Merks; T M de Reijke; P de Vries; L F A Wymenga; B Wijsman; J L Boormans
Journal:  Contemp Clin Trials Commun       Date:  2018-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.